Copanlisib dihydrochloride is a potent, selective, and ATP-competitive pan-class I PI3K inhibitor. It demonstrates over 2,000-fold selectivity against other lipid and protein kinases, excluding mTOR, and exhibits superior antitumor activity.
- Induces apoptosis in BT20 breast cancer cells
- Inhibits PI3K-mediated AKT phosphorylation in ELT3 cells
- Potently inhibits cell proliferation in human tumor cell lines
- Shows robust antitumor activity in athymic nude rats injected with KPL4 tumor cells